Dr. Shapiro’s work has appeared in a wide range of peer-reviewed journals. Below is a selection of some recent publications.

Targeted Inhibition of Select ERK1/2 Functions Mitigates Pathological Features of Asthma in Mice. Sushrut D. Shah, Ajay P. Nayak, Pawan Sharma, Dominic R. Villalba, Sankar Addya, Weiliang Huang, Paul Shapiro, Maureen A. Kane, Deepak A. Deshpande (2023) Am. J. Resp. Cell Mol. Biol. 68(1):23-38. PMID: 36067041

The ERK2 DBP domain opposes pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm. Yong Zhang, Billy Truong, Shawn P Fahl, Esteban Martinez , Kathy Cai, Essel Dulaimi, Yulan Gong, Dan A Liebermann, Jonathan Soboloff , Roland Dunbrack, Ross L Levine, Steven Fletcher, Dietmar J Kappes, Stephen Sykes, Paul Shapiro, David L Wiest (2022). Blood. Vol. 140 (4): 359-373. PMID: 35436326

Proteomic changes in monolayer and spheroid melanoma cell models of acquired resistance to BRAF and MEK1/2 inhibitors. Ramon Martinez III, Weiliang Huang, Heather Buck, Samantha Rea, Amy Defnet, Maureen Kane, Paul Shapiro (2022). ACS Omega, 7(4):3293-3311, PMID: 35128241

Dysregulated retinoic acid signaling in airway smooth muscle cells in asthma. Amy E. Defnet, Sushrut D. Shah, Weiliang Huang, Paul Shapiro, Deepak A Deshpande, and Maureen A. Kane (2021). FASEB J. Dec;35(12):e22016. doi: 10.1096/fj.202100835R. PMID: 34784434

Mechanistic analysis of an ERK2-interacting compound that inhibits mutant-BRAF expressing melanoma cells by inducing oxidative stress. Ramon Martinez III, Weiliang Huang, Ramin Samadani, Bryan Mackowiak, Garrick Centola, Lijia Chen, Ivie L. Conlon, Kellie Hom, Maureen A. Kane, Steven Fletcher, and Paul Shapiro (2020) J Pharmacol Exp Ther. 2021 Jan;376(1):84-97. PMID: 33109619

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthase. Myoung Sook Kim, Ramkishore Gernapudi, Yessenia Cedeño Cedeño, Brian M. Polster, Ramon Martinez, Paul Shapiro, Santosh Kesari, Elmar Nurmemmedov and Antonino Passaniti (2020) Oncotarget, Vol. 11. (No. 43):3863-3885. PMID: 33196708

Kinase inhibitors in the treatment of obstructive pulmonary diseases. Amy E. Defnet, Jeffrey D. Hasday, Paul Shapiro (2020) Current Opinion in Pharmacology, Vol. 511:11-18. PMID: 32361678

Next Generation Kinase Inhibitors: Moving Beyond the ATP Binding/Catalytic Sites. Paul Shapiro, editor (2020), Publisher: Springer Nature. ISBN 978-3-030-48282-4.

Effects of ATP-Competitive and Function-Selective ERK Inhibitors on Airway Smooth Muscle Cell Proliferation. Amy E. Defnet, Weiliang Huang, Steven Polischak, Santosh Kumar Yadav, Maureen A. Kane, Paul Shapiro*, and Deepak A Deshpande*. (2019) FASEB J. Jul 2:fj201900680R, PMID:312663680

A temperature-dependent conformational shift in p38α MAP kinase substrate binding region associated with changes in substrate phosphorylation profile. Deredge D, Wintrode PL, Tulapurkar ME, Nagarsekar A, Zhang Y, Weber DJ, Shapiro P, Hasday JD. J Biol Chem. 2019 Jun 18. PMID: 31213525

A promiscuous kinase inhibitor reveals secrets to cancer cell survival. Shapiro P. J Biol Chem. 2019 May 24;294(21):8674-8675. PMID: 31127063

Chk-mate on resistance to kinase inhibitors. Shapiro P. Oncotarget. 2018 Aug 3;9(60):31560-31561. PMID: 30167074

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (ulixertinib). Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ. Mol Cancer Ther. 2017 Sep 22. pii: molcanther.0456.2017. doi: 10.1158/1535-7163.MCT-17-0456. [Epub ahead of print] PMID:28939558

Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells. Li Z, Li D, Choi EY, Lapidus R, Zhang L, Huang SM, Shapiro P, Wang H. J Biol Chem. 2017 Aug 18;292(33):13890-13901. doi: 10.1074/jbc.M117.783860. Epub 2017 Jun 27. PMID:28655760

Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity. Shah NG, Tulapurkar ME, Ramarathnam A, Brophy A, Martinez R 3rd, Hom K, Hodges T, Samadani R, Singh IS, MacKerell AD Jr, Shapiro P, Hasday JD. J Immunol. 2017 Apr 15;198(8):3296-3306. doi: 10.4049/jimmunol.1602059. Epub 2017 Mar 15. PMID:28298524

Samadani R, Zhang J, Brophy A, Oashi T, Priyakumar UD, Raman EP, St John FJ, Jung KY, Fletcher S, Pozharski E, MacKerell AD, Shapiro PS (2015) Small Molecule Inhibitors of ERK-mediated Immediate Early Gene Expression and Proliferation of Melanoma Cells Expressing Mutated BRaf. Biochem J. Volume 467 (part 3), p425-438. PMID: 25695333